Booth 2075
Praha, Czech Republic
APIGENEX s.r.o. is a growing Contract Research Organization located in the centre of Europe (Prague, CZ). It split from the largest pharmaceutical R&D centre in former Czechoslovakia in 1999 and has continued in its long tradition of pharmaceutical research.
APIGENEX has been in and benefited from the continuous and close partnership with Novo Nordisk A/S Denmark in the research of treatments for diabetes/obesity for 25 years.
APIGENEX provides high quality services in pre-clinical development and early-stage discovery in three major fields - medicinal chemistry, peptide synthesis and in-vivo/ in-vitro experimental pharmacology – to both Czech and international pharmaceutical companies.
APIGENEX has recently expanded its activities to include a small-scale GMP / GLP production of highly potent API (peptides, glycopeptides).
APIGENEX has been involved in a number of research collaborations with academic institutions.
Open and interactive communication with clients is standard along with flexibility and strict confidentiality.